Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
about
Activation of neutrophils by nanoparticlesNanoparticle-based targeted therapeutics in head-and-neck cancerTherapeutic targeting of liver inflammation and fibrosis by nanomedicineOxidative Burst-Dependent NETosis Is Implicated in the Resolution of Necrosis-Associated Sterile InflammationHuman serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysisRecent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery.Nanoparticle-based targeted drug deliveryCarvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles.Magnetic nanoparticles as targeted delivery systems in oncology.Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies.Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentationApplication of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals.Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.Lipid-based carriers: manufacturing and applications for pulmonary route.Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles.Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.Nanostructured lipid carriers and their current application in targeted drug delivery.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Ciprofloxacin Controlled-Solid Lipid Nanoparticles: Characterization, In Vitro Release, and Antibacterial Activity Assessment.Immunomodulatory Nanomedicine.Paclitaxel-loaded glyceryl palmitostearate nanoparticles: in vitro release and cytotoxic activity.Studies on paclitaxel-loaded glyceryl monostearate nanoparticles.Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages-impact of phagocytosis on viability and cytokine production.Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells, and smooth muscle cellsEtoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation.Targeted SLNs for management of HIV-1 associated dementia.Preparation and characterization of camptothecin solid lipid nanoparticles.Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement.Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization.Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: part II. Effect of process variables on protein model drug encapsulation efficiency.Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary deliveryRemoval of cationic and anionic dyes from aqueous solution with magnetite/pectin and magnetite/silica/pectin hybrid nanocomposites: kinetic, isotherm and mechanism analysisNanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer TherapyBovine Serum Albumin-Loaded Chitosan/Dextran Nanoparticles: Preparation and Evaluation ofEx VivoColloidal Stability in Serum
P2860
Q26995680-18F086D0-B45B-47B6-8867-4E94D511DAEAQ26999699-73618AEF-3555-47DC-B73B-33A0724DC98DQ27000074-1CE0750A-9134-4C5F-A521-05C2B6EBE27BQ30830302-4477C243-9163-42A4-ABB3-6A6D046EEE91Q34170177-73A73A8E-8E60-460F-A3B0-2552D2D400C6Q34733880-41635C12-F407-46D8-B142-FA9B6AD27233Q35644991-EE9B9A2B-9534-4960-9786-4C4394627502Q35957617-99B392B5-6250-4E85-8A3D-8AABAD003A82Q36098273-950AFA48-8E85-468A-AEEC-54066107B374Q36177729-EC80717F-F8DF-4F64-ADE4-E177AFCC5EA7Q37004099-8C4B0D01-A6A4-4514-8FA5-2AE837FA56D2Q37036373-26D1935B-0DE1-41A5-9AC8-A4E9F974BF8AQ37361729-31F984B3-1938-4A42-98B6-B5305632B08AQ37485308-3E02EC1A-4C71-494D-A354-5CF6DDE904F2Q37646827-C62EE011-9F55-4B42-A1F7-5556BD19887EQ37914880-9844F67D-65AA-4E67-AB16-85371954B03EQ38020888-2B23AC11-BE9D-4C63-B9AA-43B4DF6B08B6Q38032893-B6CF6114-21B2-48F9-90D7-FD68B6DB7E0FQ38095485-1BDA7A5E-E1C8-42D5-902A-7DD9E94A34CFQ38199540-E8908756-12E2-4FDB-8D07-D4CBAC416810Q38210565-CD710C0E-57A3-4B29-BC27-28CBF27C40CBQ38912004-AAF5A60F-DF3E-46B3-86A2-63B7623EC4FCQ38963042-6430066A-D775-461E-9311-ABA1932A5822Q39224331-2ECDB325-2B82-4D24-BADB-44C975931A62Q39877747-D19401F0-7972-48B7-86DD-354C851121C9Q39890833-CA24C9A9-4FCA-466A-949E-CD6ACF31706EQ40539325-A4B891F6-B035-4127-AFB0-81C0BC5870D8Q41892512-414083FA-D916-4448-8764-9DB314F4B35EQ41990284-664D25F1-617F-4F6B-806E-CCE09063EA72Q42200641-13B6E696-5D63-4048-A2B5-4FB96E86765BQ42676780-123C5F40-7FD3-47DA-A3BF-07EA9E8F9A6DQ43494364-253DE5ED-2E30-403D-9D0B-4DB67E9F5CE4Q46293915-0319048E-742A-43F8-9344-B987A6FEEE1DQ47960748-49FC330B-5984-46D9-9139-803D3EEFDF8AQ57183019-B41E7234-71D4-4008-9157-C753FF46AC6CQ57377046-452A2E76-5465-47C8-8C6D-180F3DA8A31FQ58691112-6270D3B4-0A39-424F-AA0D-A8F047F88389Q59018713-B76ACA9A-FFD1-4FA1-A991-98C71BA1F282
P2860
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Phagocytic uptake and cytotoxi ...... oxamine 908 and poloxamer 407.
@en
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles
@nl
type
label
Phagocytic uptake and cytotoxi ...... oxamine 908 and poloxamer 407.
@en
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles
@nl
prefLabel
Phagocytic uptake and cytotoxi ...... oxamine 908 and poloxamer 407.
@en
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles
@nl
P2093
P2860
P1476
Phagocytic uptake and cytotoxi ...... oxamine 908 and poloxamer 407.
@en
P2093
P2860
P304
P356
10.3109/10611869609015973
P577
1996-01-01T00:00:00Z